+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 40Years +
All Genders
ID07194382

Randomized Study of Nintedanib Inhalation Solution AP02 Safety and Effects in Adults With Idiopathic Pulmonary Fibrosis

Led by Avalyn Pharma Inc. · Updated on 2026-10-15

160

Participants Needed

49

Research Sites

26 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effects of Nintedanib Solution for Inhalation AP02 on lung function and fibrosis in adults with idiopathic pulmonary fibrosis IPF. This phase 2 study aims to assess the safety, tolerability, and efficacy of AP02 by comparing two different doses to a placebo in participants 40 years or older with IPF who are either untreated or have stopped certain IPF medications for at least 3 months. Participants will be randomly assigned to one of three groups to receive either a low dose, high dose of AP02, or placebo solution via inhalation using a nebulizer twice daily for 12 weeks. The study includes a 16-week period during which participants will attend six office visits and receive one phone call for ongoing assessments and monitoring. Throughout the trial, lung function will be measured with breathing tests, and participants will complete health questionnaires. Researchers will monitor lung fibrosis through imaging scores and track disease progression over 12 weeks. Safety and health will be regularly checked by doctors during visits, ensuring careful observation of participants well-being during the study.

CONDITIONS

Brief Title

AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF

Research Team

C

Craig S Conoscenti, MD, FCCP, ATSF

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here